PL3097107T3 - Diarylowe związki makrocykliczne jako modulatory kinaz białkowych - Google Patents
Diarylowe związki makrocykliczne jako modulatory kinaz białkowychInfo
- Publication number
- PL3097107T3 PL3097107T3 PL15740510T PL15740510T PL3097107T3 PL 3097107 T3 PL3097107 T3 PL 3097107T3 PL 15740510 T PL15740510 T PL 15740510T PL 15740510 T PL15740510 T PL 15740510T PL 3097107 T3 PL3097107 T3 PL 3097107T3
- Authority
- PL
- Poland
- Prior art keywords
- modulators
- protein kinases
- macrocycles
- diaryl
- diaryl macrocycles
- Prior art date
Links
- -1 Diaryl macrocycles Chemical class 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931506P | 2014-01-24 | 2014-01-24 | |
| US201462049326P | 2014-09-11 | 2014-09-11 | |
| US201562106301P | 2015-01-22 | 2015-01-22 | |
| PCT/US2015/012597 WO2015112806A2 (en) | 2014-01-24 | 2015-01-23 | Diaryl macrocycles as modulators of protein kinases |
| EP15740510.1A EP3097107B1 (en) | 2014-01-24 | 2015-01-23 | Diaryl macrocycles as modulators of protein kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3097107T3 true PL3097107T3 (pl) | 2020-01-31 |
Family
ID=53682127
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15740510T PL3097107T3 (pl) | 2014-01-24 | 2015-01-23 | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
| PL19169041.1T PL3572416T3 (pl) | 2014-01-24 | 2015-01-23 | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
| PL19212110.1T PL3636649T3 (pl) | 2014-01-24 | 2015-01-23 | Diaryle makrocykliczne jako modulatory kinaz białkowych |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19169041.1T PL3572416T3 (pl) | 2014-01-24 | 2015-01-23 | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
| PL19212110.1T PL3636649T3 (pl) | 2014-01-24 | 2015-01-23 | Diaryle makrocykliczne jako modulatory kinaz białkowych |
Country Status (35)
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2464461T3 (es) | 2008-09-22 | 2014-06-02 | Array Biopharma, Inc. | Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa |
| SG196855A1 (en) | 2008-10-22 | 2014-02-13 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| AU2011256380C1 (en) | 2010-05-20 | 2016-09-08 | Array Biopharma Inc. | Macrocyclic compounds as Trk kinase inhibitors |
| PL3097107T3 (pl) | 2014-01-24 | 2020-01-31 | Turning Point Therapeutics, Inc. | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
| EP3699181B1 (en) | 2014-11-16 | 2023-03-01 | Array Biopharma, Inc. | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| US10758525B2 (en) | 2015-01-22 | 2020-09-01 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds |
| AU2016270803A1 (en) | 2015-06-01 | 2018-01-04 | Loxo Oncology, Inc. | Methods of diagnosing and treating cancer |
| AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| HRP20240780T1 (hr) * | 2015-07-06 | 2024-09-13 | Turning Point Therapeutics, Inc. | Polimorf diaril makrocikla |
| JP6816100B2 (ja) | 2015-07-16 | 2021-01-20 | アレイ バイオファーマ、インコーポレイテッド | ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物 |
| KR102772574B1 (ko) * | 2015-07-21 | 2025-02-24 | 터닝 포인트 테라퓨틱스, 인크. | 키랄 디아릴 매크로사이클 및 이것의 용도 |
| US10724102B2 (en) | 2015-10-26 | 2020-07-28 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
| US11278521B2 (en) | 2015-12-15 | 2022-03-22 | University Of South Florida | GAS5 binding compounds, formulations, and uses thereof |
| SG11201808559PA (en) | 2016-04-04 | 2018-10-30 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| PL3439663T3 (pl) | 2016-04-04 | 2024-11-18 | Loxo Oncology, Inc. | Sposoby leczenia nowotworów wieku dziecięcego |
| FI3800189T3 (fi) | 2016-05-18 | 2023-07-31 | Loxo Oncology Inc | (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin valmistaminen |
| RU2019105587A (ru) * | 2016-07-28 | 2020-08-28 | Тёрнинг Поинт Терапьютикс, Инк. | Макроциклические ингибиторы киназ |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| ES2948194T3 (es) | 2017-01-18 | 2023-09-01 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN107586796B (zh) * | 2017-07-20 | 2021-08-06 | 暨明医药科技（苏州）有限公司 | (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法 |
| JP7224334B2 (ja) | 2017-07-28 | 2023-02-17 | ターニング・ポイント・セラピューティクス・インコーポレイテッド | 大環式化合物およびその使用 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| WO2019084285A1 (en) | 2017-10-26 | 2019-05-02 | Qian Zhao | FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR |
| CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
| CA3081790C (en) | 2017-11-10 | 2023-03-07 | Angex Pharmaceutical, Inc. | Macrocyclic compounds as trk kinase inhibitors and uses thereof |
| EP3728270A4 (en) | 2017-12-19 | 2021-06-23 | Turning Point Therapeutics, Inc. | MACROCYCLIC KINASE INHIBITORS AND THEIR USES |
| SI3728271T1 (sl) * | 2017-12-19 | 2023-01-31 | Turning Point Therapeutics, Inc. | Makrociklične spojine za zdravljenje bolezni |
| CN111362949B (zh) | 2017-12-22 | 2021-12-21 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途 |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| US11603374B2 (en) | 2018-01-18 | 2023-03-14 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| TW201938169A (zh) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物 |
| CN111848622A (zh) | 2018-01-23 | 2020-10-30 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑并[1,5-a]嘧啶类的大环化合物 |
| TW201932472A (zh) * | 2018-01-30 | 2019-08-16 | 大陸商上海吉倍生物技術有限公司 | 具有大環分子結構的化合物及其用途 |
| CN110156813B (zh) * | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| MX2020010116A (es) * | 2018-03-28 | 2020-11-06 | Fochon Biosciences Ltd | Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk). |
| EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
| EP3770161B1 (en) * | 2018-04-16 | 2022-08-24 | Shenzhen TargetRx, Inc. | Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity |
| WO2019206069A1 (zh) * | 2018-04-25 | 2019-10-31 | 北京普祺医药科技有限公司 | 一种二芳基巨环化合物、药物组合物以及其用途 |
| WO2019210835A1 (zh) * | 2018-05-04 | 2019-11-07 | 正大天晴药业集团股份有限公司 | 作为蛋白激酶调节剂的二芳基大环化合物 |
| CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| CA3224985A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| CN110950889B (zh) * | 2018-09-27 | 2022-04-05 | 北京赛林泰医药技术有限公司 | 一种多靶点激酶抑制剂及其制备方法和用途 |
| US20210403485A1 (en) * | 2018-09-29 | 2021-12-30 | Shandong Luye Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivative as selective trk inhibitor |
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| SG11202104609SA (en) * | 2018-11-09 | 2021-06-29 | Shandong Xuanzhu Pharma Co Ltd | Macrocyclic tyrosine kinase inhibitor and uses thereof |
| CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
| AU2019385397B2 (en) * | 2018-11-19 | 2025-05-22 | Dana-Farber Cancer Institute, Inc. | Macrocyclic inhibitors of DYRK1A |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| CN113490666A (zh) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
| CN111592541B (zh) * | 2019-02-21 | 2021-09-10 | 山东轩竹医药科技有限公司 | 大环类激酶抑制剂及其用途 |
| JP7586829B2 (ja) * | 2019-03-11 | 2024-11-19 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| SG11202110523XA (en) * | 2019-03-26 | 2021-10-28 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| CN113727984B (zh) * | 2019-05-21 | 2024-03-15 | 浙江海正药业股份有限公司 | 大环类衍生物、及其制备方法和用途 |
| WO2020257189A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for treating disease |
| CA3143043A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Polymorphs of a macrocyclic kinase inhibitor |
| WO2020257165A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| CN113773335B (zh) * | 2019-06-21 | 2024-12-03 | 成都海博为药业有限公司 | 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途 |
| KR20220024694A (ko) * | 2019-06-21 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | Mcl-1의 거대환식 억제제 |
| KR20220035176A (ko) | 2019-07-16 | 2022-03-21 | 미요카디아, 인크. | (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드의 다형체 형태 |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| CN114423762B (zh) * | 2019-09-30 | 2024-03-29 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
| CA3163095A1 (en) | 2019-11-27 | 2021-06-03 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
| KR20220133866A (ko) * | 2019-11-27 | 2022-10-05 | 터닝 포인트 테라퓨틱스, 인크. | 디아릴 매크로시클릭 화합물을 수반하는 병용 요법 |
| MX2022006853A (es) * | 2019-12-03 | 2022-09-19 | Turning Point Therapeutics Inc | Macrociclos para uso en el tratamiento de enfermedades. |
| EP4069369A4 (en) | 2019-12-06 | 2024-02-14 | Schrödinger, Inc. | CYCLIC COMPOUNDS AND METHODS OF USE THEREOF |
| CN113045587A (zh) * | 2019-12-27 | 2021-06-29 | 成都倍特药业股份有限公司 | 一种大环结构化合物的晶型及其制备方法 |
| PH12022551523A1 (en) | 2019-12-27 | 2024-01-29 | SchraDinger Inc | Cyclic compounds and methods of using same |
| CN113135938B (zh) * | 2020-01-19 | 2022-06-14 | 山东轩竹医药科技有限公司 | 取代的大环类酪氨酸激酶抑制剂及其用途 |
| IL295938A (en) * | 2020-03-02 | 2022-10-01 | Turning Point Therapeutics Inc | Therapeutic uses of macrocyclic compounds |
| AU2021267161A1 (en) | 2020-05-04 | 2022-12-08 | Amgen Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
| EP4148055A4 (en) * | 2020-05-08 | 2023-10-11 | Shandong Xuanzhu Pharma Co., Ltd. | CRYSTAL FORM OF A MACROCYCLIC TYROSINE KINASE INHIBITOR AND PROCESS FOR PRODUCTION THEREOF |
| WO2021244609A1 (zh) * | 2020-06-04 | 2021-12-09 | 成都倍特药业股份有限公司 | 具有大环结构的化合物及其用途 |
| BR112023000463A2 (pt) * | 2020-07-10 | 2023-03-28 | Blossomhill Therapeutics Inc | Macrociclos e seu uso |
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| JP2024505890A (ja) | 2021-01-26 | 2024-02-08 | シュレーディンガー， インコーポレイテッド | がん、自己免疫及び炎症性障害の治療に有用な三環式化合物 |
| WO2022182845A1 (en) * | 2021-02-25 | 2022-09-01 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| CN113754657B (zh) * | 2021-09-22 | 2023-01-17 | 广州白云山医药集团股份有限公司白云山制药总厂 | 大环类化合物的晶型及其制备方法和应用 |
| CN116063326B (zh) * | 2021-11-02 | 2025-08-05 | 赛诺哈勃药业（成都）有限公司 | 作为蛋白激酶调节剂的含氨基大环化合物 |
| CN116514813A (zh) * | 2021-12-31 | 2023-08-01 | 轩竹生物科技股份有限公司 | 酪氨酸激酶抑制剂及其中间体的制备方法 |
| JP2025503592A (ja) * | 2022-01-05 | 2025-02-04 | ブロッサムヒル・セラピューティクス・インコーポレイテッド | 大環状化合物およびキナーゼ阻害剤としての使用 |
| CN115746023B (zh) * | 2022-10-27 | 2024-08-09 | 复旦大学 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
| WO2025217347A2 (en) | 2024-04-11 | 2025-10-16 | Bristol-Myers Squibb Company | Process of preparing repotrectinib |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4838925A (en) | 1986-04-25 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
| DE3861031D1 (de) | 1987-03-07 | 1990-12-20 | Bayer Ag | Verfahren zur herstellung von 5-amino-4,6-dihalogenpyridinen. |
| DK0690843T3 (da) | 1993-03-25 | 2000-11-13 | Upjohn Co | Fornyl- eller cyanosubstituerede indolderivater med dopaninerg aktivitet |
| CN1050844C (zh) | 1993-12-07 | 2000-03-29 | 伊莱利利公司 | 蛋白激酶ｃ抑制剂 |
| FR2746309B1 (fr) | 1996-03-22 | 1998-04-17 | Oreal | Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| FR2793791B1 (fr) | 1999-05-19 | 2002-01-25 | Univ Paris 7 Denis Diderot | Nouveaux composes inhibiteurs specifiques de phospholipases a2 |
| CN1277828C (zh) | 2000-07-31 | 2006-10-04 | 霍夫曼-拉罗奇有限公司 | 哌嗪衍生物 |
| US6828327B2 (en) | 2000-12-08 | 2004-12-07 | Ortho-Mcneil Pharmaceutical, Inc. | Macroheterocylic compounds useful as kinase inhibitors |
| AU2002254114A1 (en) | 2001-03-23 | 2002-10-08 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| US7970766B1 (en) | 2007-07-23 | 2011-06-28 | Google Inc. | Entity type assignment |
| US8815872B2 (en) * | 2008-09-08 | 2014-08-26 | Merck Patent Gmbh | Macrocyclics pyrimidines as aurora kinase inhibitors |
| ES2464461T3 (es) | 2008-09-22 | 2014-06-02 | Array Biopharma, Inc. | Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa |
| SG196855A1 (en) | 2008-10-22 | 2014-02-13 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| JP5769199B2 (ja) | 2008-10-31 | 2015-08-26 | ジェネンテック， インコーポレイテッド | ピラゾロピリミジンｊａｋ阻害剤化合物と方法 |
| WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| US20110029480A1 (en) | 2009-08-03 | 2011-02-03 | IntelliCubes, Inc. | Method of Compiling Multiple Data Sources into One Dataset |
| CA2777664C (en) | 2009-10-13 | 2014-06-10 | Johannes Wilhelmus J. Thuring | Macrocyclic integrase inhibitors |
| JP5643332B2 (ja) | 2009-12-07 | 2014-12-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピロロピリジンまたはベンゾイミダゾールコアを含有する複素環化合物 |
| US9150577B2 (en) | 2009-12-07 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing an indole core |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| AU2011256380C1 (en) | 2010-05-20 | 2016-09-08 | Array Biopharma Inc. | Macrocyclic compounds as Trk kinase inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| RU2014110399A (ru) | 2011-08-19 | 2015-09-27 | Мерк Шарп И Доум Корп. | Кристаллические формы вгс протеазного ингибитора |
| WO2013045701A2 (en) | 2011-09-29 | 2013-04-04 | L'oreal | Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor |
| WO2013045702A2 (en) | 2011-09-29 | 2013-04-04 | L'oreal | Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor |
| GB2495134B (en) | 2011-09-30 | 2014-06-11 | Tridonic Uk Ltd | Power supply apparatus |
| KR20140078710A (ko) | 2011-09-30 | 2014-06-25 | 온코디자인 에스.에이. | 거대고리 flt3 키나제 억제제 |
| KR20140077963A (ko) | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
| WO2013132376A1 (en) * | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| KR102085121B1 (ko) * | 2012-03-09 | 2020-03-05 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도 |
| RU2014140735A (ru) | 2012-03-09 | 2016-04-27 | Лексикон Фармасьютикалз, Инк. | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| EP2645540A1 (de) | 2012-03-28 | 2013-10-02 | Siemens Aktiengesellschaft | Glimmschutzwerkstoff für eine elektrische Maschine |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US9682995B2 (en) | 2013-01-30 | 2017-06-20 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| CN105358534A (zh) | 2013-04-23 | 2016-02-24 | 斯洛文尼亚莱柯制药股份有限公司 | 8-氯-1-甲基-苯并[d]吖庚因的新合成方法、新的中间体及其生产方法 |
| EP3026051A4 (en) | 2013-07-24 | 2017-03-08 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| PL3097107T3 (pl) | 2014-01-24 | 2020-01-31 | Turning Point Therapeutics, Inc. | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
| WO2016070241A1 (en) | 2014-11-03 | 2016-05-12 | Ctxt Pty Ltd | Triazine compounds, compositions and synthesis |
| EP4420732A3 (en) | 2014-12-15 | 2024-11-27 | CMG Pharmaceutical Co., Ltd. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| JP6800158B2 (ja) | 2015-02-20 | 2020-12-16 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｇｄｆ−８阻害剤 |
| US10329294B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of IRAK4 activity |
| EP3268367B8 (en) | 2015-03-12 | 2022-11-16 | Merck Sharp & Dohme LLC | Carboxamide inhibitors of irak4 activity |
| CA2984848A1 (en) | 2015-05-05 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| CN108289610A (zh) | 2015-06-29 | 2018-07-17 | Q-科雷医疗有限公司 | 用于感测和分析医疗装置的导管内的流体和其中的气泡的特性的方法、电路、装置、组件、系统和相关联的计算机可执行代码 |
| AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| HRP20240780T1 (hr) * | 2015-07-06 | 2024-09-13 | Turning Point Therapeutics, Inc. | Polimorf diaril makrocikla |
| KR102772574B1 (ko) | 2015-07-21 | 2025-02-24 | 터닝 포인트 테라퓨틱스, 인크. | 키랄 디아릴 매크로사이클 및 이것의 용도 |
| US10724102B2 (en) | 2015-10-26 | 2020-07-28 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
| CN109153643B (zh) | 2016-03-04 | 2022-06-21 | 范德比尔特大学 | 取代的吲哚mcl-1抑制剂 |
| RU2019105587A (ru) | 2016-07-28 | 2020-08-28 | Тёрнинг Поинт Терапьютикс, Инк. | Макроциклические ингибиторы киназ |
| EP3555137A1 (en) | 2016-12-14 | 2019-10-23 | Development Center for Biotechnology | Antibody-drug conjugates and uses thereof |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| JP7224334B2 (ja) | 2017-07-28 | 2023-02-17 | ターニング・ポイント・セラピューティクス・インコーポレイテッド | 大環式化合物およびその使用 |
-
2015
- 2015-01-23 PL PL15740510T patent/PL3097107T3/pl unknown
- 2015-01-23 HU HUE19169041A patent/HUE060554T2/hu unknown
- 2015-01-23 PT PT192121101T patent/PT3636649T/pt unknown
- 2015-01-23 UA UAA201608991A patent/UA121206C2/uk unknown
- 2015-01-23 CN CN201910549014.1A patent/CN110317213B/zh active Active
- 2015-01-23 PL PL19169041.1T patent/PL3572416T3/pl unknown
- 2015-01-23 PT PT15740510T patent/PT3097107T/pt unknown
- 2015-01-23 CN CN201910549748.XA patent/CN110317214B/zh active Active
- 2015-01-23 AU AU2015209239A patent/AU2015209239B2/en active Active
- 2015-01-23 SG SG10202000191YA patent/SG10202000191YA/en unknown
- 2015-01-23 MX MX2020001360A patent/MX392904B/es unknown
- 2015-01-23 RS RS20221161A patent/RS63829B1/sr unknown
- 2015-01-23 DK DK19212110.1T patent/DK3636649T3/da active
- 2015-01-23 ES ES19169041T patent/ES2933350T3/es active Active
- 2015-01-23 SM SM20240175T patent/SMT202400175T1/it unknown
- 2015-01-23 FI FIEP19212110.1T patent/FI3636649T3/fi active
- 2015-01-23 LT LTEP19212110.1T patent/LT3636649T/lt unknown
- 2015-01-23 EP EP15740510.1A patent/EP3097107B1/en active Active
- 2015-01-23 KR KR1020167020188A patent/KR102402179B1/ko active Active
- 2015-01-23 SI SI201530810T patent/SI3097107T1/sl unknown
- 2015-01-23 AP AP2016009383A patent/AP2016009383A0/en unknown
- 2015-01-23 CA CA2936079A patent/CA2936079C/en active Active
- 2015-01-23 HU HUE15740510A patent/HUE045208T2/hu unknown
- 2015-01-23 HR HRP20191283TT patent/HRP20191283T1/hr unknown
- 2015-01-23 EP EP19212106.9A patent/EP3636648A1/en not_active Withdrawn
- 2015-01-23 NZ NZ761094A patent/NZ761094A/en unknown
- 2015-01-23 ES ES15740510T patent/ES2735729T3/es active Active
- 2015-01-23 LT LTEP15740510.1T patent/LT3097107T/lt unknown
- 2015-01-23 EP EP19169041.1A patent/EP3572416B1/en active Active
- 2015-01-23 SI SI201531994T patent/SI3636649T1/sl unknown
- 2015-01-23 PT PT191690411T patent/PT3572416T/pt unknown
- 2015-01-23 MY MYPI2016001385A patent/MY193524A/en unknown
- 2015-01-23 NZ NZ722375A patent/NZ722375A/en unknown
- 2015-01-23 HR HRP20221518TT patent/HRP20221518T1/hr unknown
- 2015-01-23 RS RS20190900A patent/RS59059B1/sr unknown
- 2015-01-23 WO PCT/US2015/012597 patent/WO2015112806A2/en not_active Ceased
- 2015-01-23 EA EA201892241A patent/EA201892241A1/ru unknown
- 2015-01-23 ES ES19212110T patent/ES2976459T3/es active Active
- 2015-01-23 CN CN201580005705.5A patent/CN106170289B/zh active Active
- 2015-01-23 SG SG11201605929RA patent/SG11201605929RA/en unknown
- 2015-01-23 HU HUE19212110A patent/HUE066590T2/hu unknown
- 2015-01-23 LT LTEP19169041.1T patent/LT3572416T/lt unknown
- 2015-01-23 RS RS20240447A patent/RS65417B1/sr unknown
- 2015-01-23 PL PL19212110.1T patent/PL3636649T3/pl unknown
- 2015-01-23 DK DK15740510.1T patent/DK3097107T3/da active
- 2015-01-23 SM SM20190388T patent/SMT201900388T1/it unknown
- 2015-01-23 JP JP2016566857A patent/JP6490713B2/ja active Active
- 2015-01-23 HR HRP20240503TT patent/HRP20240503T1/hr unknown
- 2015-01-23 EP EP19212110.1A patent/EP3636649B1/en active Active
- 2015-01-23 EA EA201691492A patent/EA031863B1/ru active IP Right Revival
- 2015-01-23 SI SI201531908T patent/SI3572416T1/sl unknown
- 2015-01-23 EP EP23220719.1A patent/EP4338739A3/en active Pending
- 2015-01-23 DK DK19169041.1T patent/DK3572416T3/da active
- 2015-01-23 MX MX2016009588A patent/MX2016009588A/es active IP Right Grant
- 2015-01-23 US US15/113,583 patent/US9714258B2/en not_active Ceased
- 2015-01-23 SM SM20230008T patent/SMT202300008T1/it unknown
- 2015-01-23 EP EP19212126.7A patent/EP3636650A1/en not_active Withdrawn
- 2015-01-23 PE PE2016000959A patent/PE20160931A1/es unknown
- 2015-01-23 US US18/147,888 patent/USRE50634E1/en active Active
-
2016
- 2016-07-07 ZA ZA2016/04654A patent/ZA201604654B/en unknown
- 2016-07-20 IL IL246860A patent/IL246860B/en active IP Right Grant
- 2016-07-22 CL CL2016001876A patent/CL2016001876A1/es unknown
- 2016-07-25 PH PH12016501463A patent/PH12016501463A1/en unknown
-
2017
- 2017-05-31 US US15/609,962 patent/US10246466B2/en active Active
-
2018
- 2018-11-29 US US16/204,566 patent/US10618912B2/en active Active
-
2019
- 2019-02-27 JP JP2019034652A patent/JP2019104748A/ja not_active Withdrawn
- 2019-07-17 CY CY20191100764T patent/CY1121850T1/el unknown
- 2019-08-21 IL IL268820A patent/IL268820B/en unknown
- 2019-12-10 AU AU2019279951A patent/AU2019279951B2/en active Active
-
2020
- 2020-02-21 US US16/797,866 patent/US20200216465A1/en not_active Abandoned
- 2020-07-06 ZA ZA2020/04100A patent/ZA202004100B/en unknown
-
2021
- 2021-01-07 JP JP2021001588A patent/JP2021063121A/ja active Pending
- 2021-09-27 US US17/485,942 patent/US20220112213A1/en not_active Abandoned
-
2022
- 2022-07-08 JP JP2022110613A patent/JP7356546B2/ja active Active
-
2023
- 2023-07-28 US US18/227,561 patent/US12404281B2/en active Active
- 2023-09-22 JP JP2023158350A patent/JP2023179539A/ja not_active Ceased
-
2025
- 2025-03-12 NL NL301322C patent/NL301322I2/nl unknown
- 2025-03-13 NO NO2025015C patent/NO2025015I1/no unknown
- 2025-03-20 HU HUS2500016C patent/HUS2500016I1/hu unknown
- 2025-03-20 FI FIC20250015C patent/FIC20250015I1/fi unknown
- 2025-04-08 LT LTPA2025513C patent/LTPA2025513I1/lt unknown
- 2025-04-09 FR FR25C1013C patent/FR25C1013I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500016I1 (hu) | Diaril-makrociklusok mint proteinkináz-modulátorok | |
| IL256377A (en) | Diaryl chiral macrocycles as protein kinase modulators | |
| IL259421B (en) | ror - gamma modulators | |
| IL258013A (en) | Modulators of kras expression | |
| IL252417A0 (en) | Use of erythrohydroxybupropion to increase plasma drug level | |
| IL262381A (en) | 6-Aminopyridin-3-yl thiazoles as ror-gamma-t modulators | |
| EP3178923A4 (en) | Use of susd2 protein as marker | |
| IL247234A0 (en) | Caspase-6 modulators | |
| GB201620640D0 (en) | Vacuum-deposited modification of polymer surfaces | |
| EP3200955A4 (en) | Methods of polishing | |
| SG11201607445QA (en) | Methods of modulating wars2 | |
| PT3377106T (pt) | Modulação da ciliogénese | |
| GB201418230D0 (en) | Construction of surfaces | |
| GB201407888D0 (en) | Novel specific kinase modulators | |
| GB201406276D0 (en) | Making of land |